Risperdal Withdrawal & Tapering Guide
risperidone
Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis.
In short
Risperdal (risperidone) is an Atypical Antipsychotic with a half-life of 3–20 hours. Liquid formulation (1mg/mL) available for precise dosing. It is also sold as Risperdal Consta.
- Class
- Atypical Antipsychotic
- Half-life
- 3–20 hours
- Common doses
- 0.5mg, 1mg, 2mg, 3mg, 4mg
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Risperidone is an atypical antipsychotic approved for schizophrenia, bipolar mania, and irritability associated with autistic disorder. It has high affinity for dopamine D2 and serotonin 5-HT2A receptors and carries a notable risk of hyperprolactinemia.
0.5mg, 1mg, 2mg, 3mg, 4mg
Tablets: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; Orally disintegrating tablets (M-Tab): 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg; Oral solution: 1mg/mL; Long-acting injection (Risperdal Consta): 12.5mg, 25mg, 37.5mg, 50mg
Category C (risk cannot be ruled out)
Mechanism of Action
Potent antagonist at dopamine D2 and serotonin 5-HT2A receptors. Also antagonizes alpha-1, alpha-2 adrenergic, and histamine H1 receptors. Higher D2 affinity than most atypicals contributes to EPS risk at higher doses and hyperprolactinemia.
Taper Notes
Liquid formulation (1mg/mL) available for precise dosing. Withdrawal can include supersensitivity psychosis.
Hyperbolic Tapering Guidance
Oral solution provides precise dosing. Extremely gradual taper essential, especially for long-term use. Risk of dopamine supersensitivity.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- CYP2D6 inhibitors (fluoxetine, paroxetine) increase risperidone levels
- CYP3A4 inducers (carbamazepine, phenytoin, rifampin) decrease risperidone levels
- CYP3A4 inhibitors (ketoconazole, itraconazole) increase risperidone levels
Food Interactions
- Food does not significantly affect absorption
- Avoid alcohol (additive CNS depression)
Contraindications
- Known hypersensitivity to risperidone or paliperidone
Toxicity
Hyperprolactinemia (highest among atypicals). Extrapyramidal symptoms at higher doses. Metabolic effects (weight gain, hyperglycemia, dyslipidemia). Orthostatic hypotension. Tardive dyskinesia. NMS rarely.
Pharmacokinetics
ADME Profile
Well absorbed after oral administration. Bioavailability ~70% (oral solution) to ~66% (tablets). Tmax ~1 hour. Food does not significantly affect absorption.
~1–2 L/kg
Hepatic via CYP2D6 (primary) to the active metabolite 9-hydroxyrisperidone (paliperidone), which has similar pharmacological activity. CYP3A4 is a minor pathway.
Renal (~70%) and fecal (~14%). In extensive CYP2D6 metabolizers, active moiety (risperidone + 9-OH-risperidone) half-life is ~20 hours.
~90% (risperidone), ~77% (9-hydroxyrisperidone)
~5–8 mL/min/kg (total active moiety clearance)
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing Atypical Antipsychotic medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 2 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (2 mg start) |
|---|---|---|
| Start | 100% | 2 mg |
| Step 1 | 90% | 1.8 mg |
| Step 2 | 81% | 1.62 mg |
| Step 3 | 73% | 1.46 mg |
| Step 4 | 66% | 1.31 mg |
| Step 5 | 59% | 1.18 mg |
| Step 6 | 53% | 1.06 mg |
| Step 7 | 48% | 0.957 mg |
| Step 8 | 43% | 0.861 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Risperdal, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Risperdal
What are the withdrawal symptoms of Risperdal (risperidone)?
Common withdrawal symptoms of Risperdal (risperidone) include: insomnia, nausea, anxiety, psychosis risk, movement disorders. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Risperdal (risperidone)?
Liquid formulation (1mg/mL) available for precise dosing. Withdrawal can include supersensitivity psychosis. Oral solution provides precise dosing. Extremely gradual taper essential, especially for long-term use. Risk of dopamine supersensitivity.
Can I stop Risperdal cold turkey?
Stopping Risperdal abruptly is not recommended. Its half-life is 3–20 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Risperdal stay in your system?
Risperdal (risperidone) has a half-life of 3–20 hours. A drug is mostly cleared after about five half-lives, so Risperdal is largely out of the body roughly 15 hours to 4 days after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Recent discussions about Risperdal
What members tapering Risperdal are asking and reporting right now. Personal experience, not medical advice.
- Risperidal Tapering ThreadThis is the forum for everyone tapering Risperidal. When you log a check-in in My Taper, it will appear here. That way you can see how others on the same medication are…Based · 5 days ago · 8 replies
- Risperdone tradeMy doc is changing my Risperdone to ziprazedone due adverse effects. he said that ziprazedone is low TD. Any information?Fake Psychiatry 35 · 2 months ago · 1 reply
Sources & References
Risperdal (risperidone) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.